HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 288/4/H1937    most recent 01076.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Gorman, M. W. Articles by Feigl, E. O. Search for Related Content PubMed PubMed Citation Articles by Gorman, M. W. Articles by Feigl, E. O.

Role of endothelin in -adrenoceptor coronary vasoconstriction

Department of Physiology and Biophysics, University of Washington School of Medicine, Seattle, Washington

Submitted 21 October 2004 ; accepted in final form 2 December 2004

It has been proposed that -adrenoceptor vasoconstriction in coronary resistance vessels results not from -adrenoceptors on coronary smooth muscle but from -adrenoceptors on cardiac myocytes that stimulate endothelin (ET) release. The present experiments tested the hypothesis that the -adrenoceptor-mediated coronary vasoconstriction that normally occurs during exercise is due to endothelin. In conscious dogs (n = 10), the endothelin ET_A/ET_B receptor antagonist tezosentan (1 mg/kg iv) increased coronary venous oxygen tension at rest but not during treadmill exercise. This result indicates that basal endothelin levels produce a coronary vasoconstriction at rest that is not observed during the coronary vasodilation during exercise. In contrast, the -adrenoceptor antagonist phentolamine increased coronary venous oxygen tension during exercise but not at rest. The difference between the endothelin blockade and -adrenoceptor blockade results indicates that -adrenoceptor coronary vasoconstriction during exercise is not due to endothelin. However, in anesthetized dogs, bolus intracoronary injections of the -adrenoceptor agonist phenylephrine produced reductions in coronary blood flow that were partially antagonized by endothelin receptor blockade with tezosentan. These results are best explained if -adrenoceptor-induced endothelin release requires high pharmacological concentrations of catecholamines that are not reached during exercise.

coronary blood flow; exercise; tezosentan; dogs; norepinephrine

This article has been cited by other articles:

				D. J. Duncker and R. J. Bache Regulation of Coronary Blood Flow During Exercise Physiol Rev, July 1, 2008; 88(3): 1009 - 1086. [Abstract] [Full Text] [PDF]

				D. Merkus, D. B. Haitsma, O. Sorop, F. Boomsma, V. J. de Beer, J. M. J. Lamers, P. D. Verdouw, and D. J. Duncker Coronary vasoconstrictor influence of angiotensin II is reduced in remodeled myocardium after myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2082 - H2089. [Abstract] [Full Text] [PDF]

				J. D. Tune Withdrawal of vasoconstrictor influences in local metabolic coronary vasodilation Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2044 - H2046. [Full Text] [PDF]